Literature DB >> 8774051

Gaucher disease: four families with previously undescribed mutations.

E Beutler1, T Gelbart, D Balicki, A Demina, J Adusumalli, L Elsas, K A Grinzaid, R Gitzelmann, A Superti-Furga, C Kattamis, B B Liou.   

Abstract

We describe four families with patients with type I Gaucher disease exhibiting previously undescribed mutations of the glucocerebrosidase gene. We found Cherokee Indian woman to have a G-->C substitution in cDNA nucleotide 354, predicting a lysine-->aspargine substitution in amino acid 79 of the processed protein. In a Greek family, we found an allele with a C-->T substitution in nucleotide 475 giving rise to an arginine-->tryptophan substitution at amino acid 120. In another non-Jewish European patient, we identified a C-->T substitution in nucleotide 1223, predicting a threonine-->methionine mutation in amino acid 369. We found two non-Jewish European children to have a C-->T mutation at nucleotide 1357, predicting termination at codon 414. Although siblings carry the same two glucocerebrosidase mutations, in these families as in others we noted considerable differences in severity of clinical manifestations. Finding the reason for these differences is an important goal in the study of Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774051

Source DB:  PubMed          Journal:  Proc Assoc Am Physicians        ISSN: 1081-650X


  4 in total

1.  Newborn screening for lysosomal storage disorders in hungary.

Authors:  Judit Wittmann; Eszter Karg; Sàndor Turi; Elisa Legnini; Gyula Wittmann; Anne-Katrin Giese; Jan Lukas; Uta Gölnitz; Michael Klingenhäger; Olaf Bodamer; Adolf Mühl; Arndt Rolfs
Journal:  JIMD Rep       Date:  2012-03-21

2.  Type 2 Gaucher disease: the collodion baby phenotype revisited.

Authors:  D L Stone; W F Carey; J Christodoulou; D Sillence; P Nelson; M Callahan; N Tayebi; E Sidransky
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

3.  CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.

Authors:  Thomas A Burrow; Ying Sun; Carlos E Prada; Laurie Bailey; Wujuan Zhang; Amanda Brewer; Steve W Wu; Kenneth D R Setchell; David Witte; Mitchell B Cohen; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2014-09-02       Impact factor: 4.797

4.  Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease.

Authors:  James M Gruschus
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.